ID   FOXO1_HUMAN             Reviewed;         655 AA.
AC   Q12778; O43523; Q5VYC7; Q6NSK6;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   18-JUN-2025, entry version 238.
DE   RecName: Full=Forkhead box protein O1 {ECO:0000305};
DE   AltName: Full=Forkhead box protein O1A;
DE   AltName: Full=Forkhead in rhabdomyosarcoma {ECO:0000303|PubMed:8275086};
GN   Name=FOXO1 {ECO:0000303|PubMed:12228231, ECO:0000312|HGNC:HGNC:3819};
GN   Synonyms=FKHR {ECO:0000303|PubMed:9479491}, FOXO1A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CHROMOSOMAL TRANSLOCATION WITH PAX3.
RX   PubMed=8275086; DOI=10.1038/ng1193-230;
RA   Galili N., Davis R.J., Fredericks W.J., Mukhopadhyay S., Rauscher F.J. III,
RA   Emanuel B.S., Rovera G., Barr F.G.;
RT   "Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar
RT   rhabdomyosarcoma.";
RL   Nat. Genet. 5:230-235(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Rhabdomyosarcoma;
RX   PubMed=9479491; DOI=10.1006/geno.1997.5122;
RA   Anderson M.J., Viars C.S., Czekay S., Cavenee W.K., Arden K.C.;
RT   "Cloning and characterization of three human forkhead genes that comprise
RT   an FKHR-like gene subfamily.";
RL   Genomics 47:187-199(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S.,
RA   Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C.,
RA   Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P.,
RA   Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L.,
RA   Frankish A.G., Frankland J., French L., Garner P., Garnett J.,
RA   Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M.,
RA   Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D.,
RA   Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D.,
RA   Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S.,
RA   Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R.,
RA   Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W.,
RA   Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L.,
RA   Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R.,
RA   Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lymph, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   CHROMOSOMAL TRANSLOCATION WITH PAX7.
RX   PubMed=8187070;
RA   Davis R.J., D'Cruz C.M., Lovell M.A., Biegel J.A., Barr F.G.;
RT   "Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in
RT   alveolar rhabdomyosarcoma.";
RL   Cancer Res. 54:2869-2872(1994).
RN   [7]
RP   PHOSPHORYLATION AT THR-24; SER-256 AND SER-319.
RX   PubMed=10358075; DOI=10.1074/jbc.274.24.17179;
RA   Rena G., Guo S., Cichy S.C., Unterman T.G., Cohen P.;
RT   "Phosphorylation of the transcription factor forkhead family member FKHR by
RT   protein kinase B.";
RL   J. Biol. Chem. 274:17179-17183(1999).
RN   [8]
RP   DNA-BINDING, PHOSPHORYLATION AT SER-256, AND FUNCTION.
RX   PubMed=10358076; DOI=10.1074/jbc.274.24.17184;
RA   Guo S., Rena G., Cichy S., He X., Cohen P., Unterman T.;
RT   "Phosphorylation of serine 256 by protein kinase B disrupts transactivation
RT   by FKHR and mediates effects of insulin on insulin-like growth factor-
RT   binding protein-1 promoter activity through a conserved insulin response
RT   sequence.";
RL   J. Biol. Chem. 274:17184-17192(1999).
RN   [9]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-329, AND MUTAGENESIS OF
RP   SER-329.
RX   PubMed=11311120; DOI=10.1042/bj3550597;
RA   Woods Y.L., Rena G., Morrice N., Barthel A., Becker W., Guo S.,
RA   Unterman T.G., Cohen P.;
RT   "The kinase DYRK1A phosphorylates the transcription factor FKHR at Ser329
RT   in vitro, a novel in vivo phosphorylation site.";
RL   Biochem. J. 355:597-607(2001).
RN   [10]
RP   INTERACTION WITH YWHAG AND YWHAZ, PHOSPHORYLATION AT THR-24; SER-256 AND
RP   SER-319, SUBCELLULAR LOCATION, AND MUTAGENESIS OF THR-24; SER-256 AND
RP   SER-319.
RX   PubMed=11237865; DOI=10.1042/0264-6021:3540605;
RA   Rena G., Prescott A.R., Guo S., Cohen P., Unterman T.G.;
RT   "Roles of the forkhead in rhabdomyosarcoma (FKHR) phosphorylation sites in
RT   regulating 14-3-3 binding, transactivation and nuclear targetting.";
RL   Biochem. J. 354:605-612(2001).
RN   [11]
RP   PHOSPHORYLATION AT THR-24; SER-256; SER-319; SER-322; SER-325 AND SER-329.
RX   PubMed=11980723; DOI=10.1093/emboj/21.9.2263;
RA   Rena G., Woods Y.L., Prescott A.R., Peggie M., Unterman T.G.,
RA   Williams M.R., Cohen P.;
RT   "Two novel phosphorylation sites on FKHR that are critical for its nuclear
RT   exclusion.";
RL   EMBO J. 21:2263-2271(2002).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF THR-24; LYS-245;
RP   LYS-248; 251-ARG--ARG-253; SER-256; LYS-262; LYS-265; LYS-274 AND SER-319.
RX   PubMed=12228231; DOI=10.1074/jbc.m208063200;
RA   Zhang X., Gan L., Pan H., Guo S., He X., Olson S.T., Mesecar A., Adam S.,
RA   Unterman T.G.;
RT   "Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1)
RT   by multiple mechanisms. Direct and indirect effects on nuclear/cytoplasmic
RT   shuttling and DNA binding.";
RL   J. Biol. Chem. 277:45276-45284(2002).
RN   [13]
RP   INTERACTION WITH CREBBP AND SIRT1, ACETYLATION, DEACETYLATION, AND
RP   FUNCTION.
RX   PubMed=15220471; DOI=10.1073/pnas.0400593101;
RA   Daitoku H., Hatta M., Matsuzaki H., Aratani S., Ohshima T., Miyagishi M.,
RA   Nakajima T., Fukamizu A.;
RT   "Silent information regulator 2 potentiates Foxo1-mediated transcription
RT   through its deacetylase activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:10042-10047(2004).
RN   [14]
RP   INTERACTION WITH EP300, ACETYLATION, SUBCELLULAR LOCATION, PHOSPHORYLATION,
RP   AND FUNCTION.
RX   PubMed=15890677; DOI=10.1210/me.2004-0292;
RA   Perrot V., Rechler M.M.;
RT   "The coactivator p300 directly acetylates the forkhead transcription factor
RT   Foxo1 and stimulates Foxo1-induced transcription.";
RL   Mol. Endocrinol. 19:2283-2298(2005).
RN   [15]
RP   INTERACTION WITH SKP2, UBIQUITINATION, AND MUTAGENESIS OF SER-256.
RX   PubMed=15668399; DOI=10.1073/pnas.0406789102;
RA   Huang H., Regan K.M., Wang F., Wang D., Smith D.I., van Deursen J.M.,
RA   Tindall D.J.;
RT   "Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated
RT   degradation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:1649-1654(2005).
RN   [16]
RP   FUNCTION.
RX   PubMed=17024043; DOI=10.1038/nature05288;
RA   Schilling M.M., Oeser J.K., Boustead J.N., Flemming B.P., O'Brien R.M.;
RT   "Gluconeogenesis: re-evaluating the FOXO1-PGC-1alpha connection.";
RL   Nature 443:E10-E11(2006).
RN   [17]
RP   INTERACTION WITH PRMT1.
RX   PubMed=18951090; DOI=10.1016/j.molcel.2008.09.013;
RA   Yamagata K., Daitoku H., Takahashi Y., Namiki K., Hisatake K., Kako K.,
RA   Mukai H., Kasuya Y., Fukamizu A.;
RT   "Arginine methylation of FOXO transcription factors inhibits their
RT   phosphorylation by Akt.";
RL   Mol. Cell 32:221-231(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [19]
RP   FUNCTION, PHOSPHORYLATION AT SER-249 BY CDK1, INTERACTION WITH CDK1 AND
RP   14-3-3 PROTEINS, AND MUTAGENESIS OF SER-249.
RX   PubMed=18356527; DOI=10.1126/science.1152337;
RA   Yuan Z., Becker E.B.E., Merlo P., Yamada T., DiBacco S., Konishi Y.,
RA   Schaefer E.M., Bonni A.;
RT   "Activation of FOXO1 by Cdk1 in cycling cells and postmitotic neurons.";
RL   Science 319:1665-1668(2008).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [21]
RP   FUNCTION, INTERACTION WITH STUB1, TISSUE SPECIFICITY, UBIQUITINATION, AND
RP   MUTAGENESIS OF THR-24; SER-256 AND SER-319.
RX   PubMed=19483080; DOI=10.1074/jbc.m109.017046;
RA   Li F., Xie P., Fan Y., Zhang H., Zheng L., Gu D., Patterson C., Li H.;
RT   "C terminus of Hsc70-interacting protein promotes smooth muscle cell
RT   proliferation and survival through ubiquitin-mediated degradation of
RT   FoxO1.";
RL   J. Biol. Chem. 284:20090-20098(2009).
RN   [22]
RP   PHOSPHORYLATION AT SER-212, SUBCELLULAR LOCATION, FUNCTION, AND MUTAGENESIS
RP   OF SER-212.
RX   PubMed=19221179; DOI=10.1074/jbc.m900461200;
RA   Yuan Z., Lehtinen M.K., Merlo P., Villen J., Gygi S., Bonni A.;
RT   "Regulation of neuronal cell death by MST1-FOXO1 signaling.";
RL   J. Biol. Chem. 284:11285-11292(2009).
RN   [23]
RP   ACETYLATION AT LYS-262; LYS-265 AND LYS-274, DEACETYLATION BY SIRT2,
RP   FUNCTION IN AUTOPHAGY, SUBCELLULAR LOCATION, AND INTERACTION WITH SIRT2 AND
RP   ATG7.
RX   PubMed=20543840; DOI=10.1038/ncb2069;
RA   Zhao Y., Yang J., Liao W., Liu X., Zhang H., Wang S., Wang D., Feng J.,
RA   Yu L., Zhu W.G.;
RT   "Cytosolic FoxO1 is essential for the induction of autophagy and tumour
RT   suppressor activity.";
RL   Nat. Cell Biol. 12:665-675(2010).
RN   [24]
RP   INDUCTION.
RX   PubMed=20668652; DOI=10.1371/journal.pone.0011786;
RA   Goitre L., Balzac F., Degani S., Degan P., Marchi S., Pinton P.,
RA   Retta S.F.;
RT   "KRIT1 regulates the homeostasis of intracellular reactive oxygen
RT   species.";
RL   PLoS ONE 5:E11786-E11786(2010).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [26]
RP   FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT SER-212.
RX   PubMed=21245099; DOI=10.1158/0008-5472.can-10-2203;
RA   Valis K., Prochazka L., Boura E., Chladova J., Obsil T., Rohlena J.,
RA   Truksa J., Dong L.F., Ralph S.J., Neuzil J.;
RT   "Hippo/Mst1 stimulates transcription of the proapoptotic mediator NOXA in a
RT   FoxO1-dependent manner.";
RL   Cancer Res. 71:946-954(2011).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [29]
RP   ACETYLATION AT LYS-423, DEACETYLATION BY SIRT6, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF LYS-423; LYS-446; LYS-463 AND LYS-515.
RX   PubMed=25009184; DOI=10.1073/pnas.1411026111;
RA   Zhang P., Tu B., Wang H., Cao Z., Tang M., Zhang C., Gu B., Li Z., Wang L.,
RA   Yang Y., Zhao Y., Wang H., Luo J., Deng C.X., Gao B., Roeder R.G.,
RA   Zhu W.G.;
RT   "Tumor suppressor p53 cooperates with SIRT6 to regulate gluconeogenesis by
RT   promoting FoxO1 nuclear exclusion.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:10684-10689(2014).
RN   [30]
RP   FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-256,
RP   DEPHOSPHORYLATION AT SER-256, AND INTERACTION WITH PPIA.
RX   PubMed=31063815; DOI=10.1016/j.cellsig.2019.04.014;
RA   Xie Y., Li X., Ge J.;
RT   "Cyclophilin A-FoxO1 signaling pathway in endothelial cell apoptosis.";
RL   Cell. Signal. 61:57-65(2019).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 151-266, DNA-BINDING,
RP   PHOSPHORYLATION AT SER-212; SER-218; SER-234 AND SER-235, ACETYLATION,
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND MUTAGENESIS OF SER-249.
RX   PubMed=18786403; DOI=10.1016/j.str.2008.06.013;
RA   Brent M.M., Anand R., Marmorstein R.;
RT   "Structural basis for DNA recognition by FoxO1 and its regulation by
RT   posttranslational modification.";
RL   Structure 16:1407-1416(2008).
CC   -!- FUNCTION: Transcription factor that is the main target of insulin
CC       signaling and regulates metabolic homeostasis in response to oxidative
CC       stress (PubMed:10358076, PubMed:12228231, PubMed:15220471,
CC       PubMed:15890677, PubMed:18356527, PubMed:19221179, PubMed:20543840,
CC       PubMed:21245099). Binds to the insulin response element (IRE) with
CC       consensus sequence 5'-TT[G/A]TTTTG-3' and the related Daf-16 family
CC       binding element (DBE) with consensus sequence 5'-TT[G/A]TTTAC-3'
CC       (PubMed:10358076). Activity suppressed by insulin (PubMed:10358076).
CC       Main regulator of redox balance and osteoblast numbers and controls
CC       bone mass (By similarity). Orchestrates the endocrine function of the
CC       skeleton in regulating glucose metabolism (By similarity). Also acts as
CC       a key regulator of chondrogenic commitment of skeletal progenitor cells
CC       in response to lipid availability: when lipids levels are low,
CC       translocates to the nucleus and promotes expression of SOX9, which
CC       induces chondrogenic commitment and suppresses fatty acid oxidation (By
CC       similarity). Acts synergistically with ATF4 to suppress
CC       osteocalcin/BGLAP activity, increasing glucose levels and triggering
CC       glucose intolerance and insulin insensitivity (By similarity). Also
CC       suppresses the transcriptional activity of RUNX2, an upstream activator
CC       of osteocalcin/BGLAP (By similarity). Acts as an inhibitor of glucose
CC       sensing in pancreatic beta cells by acting as a transcription repressor
CC       and suppressing expression of PDX1 (By similarity). In hepatocytes,
CC       promotes gluconeogenesis by acting together with PPARGC1A and CEBPA to
CC       activate the expression of genes such as IGFBP1, G6PC1 and PCK1 (By
CC       similarity). Also promotes gluconeogenesis by directly promoting
CC       expression of PPARGC1A and G6PC1 (PubMed:17024043). Important regulator
CC       of cell death acting downstream of CDK1, PKB/AKT1 and STK4/MST1
CC       (PubMed:18356527, PubMed:19221179). Promotes neural cell death
CC       (PubMed:18356527). Mediates insulin action on adipose tissue (By
CC       similarity). Regulates the expression of adipogenic genes such as PPARG
CC       during preadipocyte differentiation and, adipocyte size and adipose
CC       tissue-specific gene expression in response to excessive calorie intake
CC       (By similarity). Regulates the transcriptional activity of GADD45A and
CC       repair of nitric oxide-damaged DNA in beta-cells (By similarity).
CC       Required for the autophagic cell death induction in response to
CC       starvation or oxidative stress in a transcription-independent manner
CC       (PubMed:20543840). Mediates the function of MLIP in cardiomyocytes
CC       hypertrophy and cardiac remodeling (By similarity). Positive regulator
CC       of apoptosis in cardiac smooth muscle cells as a result of its
CC       transcriptional activation of pro-apoptotic genes (PubMed:19483080).
CC       Regulates endothelial cell (EC) viability and apoptosis in a PPIA/CYPA-
CC       dependent manner via transcription of CCL2 and BCL2L11 which are
CC       involved in EC chemotaxis and apoptosis (PubMed:31063815).
CC       {ECO:0000250|UniProtKB:A4L7N3, ECO:0000250|UniProtKB:G3V7R4,
CC       ECO:0000250|UniProtKB:Q9R1E0, ECO:0000269|PubMed:10358076,
CC       ECO:0000269|PubMed:12228231, ECO:0000269|PubMed:15220471,
CC       ECO:0000269|PubMed:15890677, ECO:0000269|PubMed:17024043,
CC       ECO:0000269|PubMed:18356527, ECO:0000269|PubMed:19221179,
CC       ECO:0000269|PubMed:19483080, ECO:0000269|PubMed:20543840,
CC       ECO:0000269|PubMed:21245099, ECO:0000269|PubMed:31063815}.
CC   -!- SUBUNIT: Interacts with LRPPRC. Interacts with RUNX2; the interaction
CC       inhibits RUNX2 transcriptional activity and mediates the IGF1/insulin-
CC       dependent BGLAP expression in osteoblasts Interacts with PPP2R1A; the
CC       interaction regulates the dephosphorylation of FOXO1 at Thr-24 and Ser-
CC       256 leading to its nuclear import. Interacts (acetylated form) with
CC       PPARG. Interacts with XBP1 isoform 2; this interaction is direct and
CC       leads to FOXO1 ubiquitination and degradation via the proteasome
CC       pathway (By similarity). Interacts with NLK. Interacts with SIRT1; the
CC       interaction results in the deacetylation of FOXO1 leading to activation
CC       of FOXO1-mediated transcription of genes involved in DNA repair and
CC       stress resistance. Binds to CDK1. Interacts with the 14-3-3 proteins,
CC       YWHAG and YWHAZ; the interactions require insulin-stimulated
CC       phosphorylation on Thr-24, promote nuclear exit and loss of
CC       transcriptional activity. Interacts with SKP2; the interaction
CC       ubiquitinates FOXO1 leading to its proteasomal degradation. The
CC       interaction requires the presence of KRIT1. Interacts (via the C-
CC       terminal half) with ATF4 (via its DNA-binding domain); the interaction
CC       occurs in osteoblasts, regulates glucose homeostasis via suppression of
CC       beta-cell proliferation and subsequent decrease in insulin production.
CC       Interacts with PRMT1; the interaction methylates FOXO1, prevents
CC       PKB/AKT1 phosphorylation and retains FOXO1 in the nucleus. Interacts
CC       with EP300 and CREBBP; the interactions acetylate FOXO1. Interacts with
CC       SIRT2; the interaction is disrupted in response to oxidative stress or
CC       serum deprivation, leading to increased level of acetylated FOXO1,
CC       which promotes stress-induced autophagy by stimulating E1-like
CC       activating enzyme ATG7. Interacts (acetylated form) with ATG7; the
CC       interaction is increased in response to oxidative stress or serum
CC       deprivation and promotes the autophagic process leading to cell death.
CC       Interacts (via the Fork-head domain) with CEBPA; the interaction
CC       increases when FOXO1 is deacetylated. Interacts with WDFY2. Forms a
CC       complex with WDFY2 and AKT1 (By similarity). Interacts with CRY1 (By
CC       similarity). Interacts with PPIA/CYPA; the interaction promotes FOXO1
CC       dephosphorylation, nuclear accumulation and transcriptional activity
CC       (PubMed:31063815). Interacts with TOX4; FOXO1 is required for full
CC       induction of TOX4-dependent activity and the interaction is inhibited
CC       by insulin (By similarity). Interacts (when phosphorylated on Ser-256)
CC       with STUB1/CHIP (PubMed:19483080). {ECO:0000250|UniProtKB:Q9R1E0,
CC       ECO:0000269|PubMed:11237865, ECO:0000269|PubMed:15220471,
CC       ECO:0000269|PubMed:15668399, ECO:0000269|PubMed:15890677,
CC       ECO:0000269|PubMed:18356527, ECO:0000269|PubMed:18951090,
CC       ECO:0000269|PubMed:19483080, ECO:0000269|PubMed:20543840,
CC       ECO:0000269|PubMed:31063815}.
CC   -!- INTERACTION:
CC       Q12778; P31749: AKT1; NbExp=2; IntAct=EBI-1108782, EBI-296087;
CC       Q12778; P06493: CDK1; NbExp=5; IntAct=EBI-1108782, EBI-444308;
CC       Q12778; Q92793: CREBBP; NbExp=3; IntAct=EBI-1108782, EBI-81215;
CC       Q12778; P03372: ESR1; NbExp=2; IntAct=EBI-1108782, EBI-78473;
CC       Q12778; P14921-3: ETS1; NbExp=2; IntAct=EBI-1108782, EBI-21403286;
CC       Q12778; Q14192: FHL2; NbExp=8; IntAct=EBI-1108782, EBI-701903;
CC       Q12778; Q01105: SET; NbExp=5; IntAct=EBI-1108782, EBI-1053182;
CC       Q12778; Q96EB6: SIRT1; NbExp=4; IntAct=EBI-1108782, EBI-1802965;
CC       Q12778; P62258: YWHAE; NbExp=5; IntAct=EBI-1108782, EBI-356498;
CC       Q12778; P63104: YWHAZ; NbExp=6; IntAct=EBI-1108782, EBI-347088;
CC       Q12778; Q923E4: Sirt1; Xeno; NbExp=2; IntAct=EBI-1108782, EBI-1802585;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:11237865,
CC       ECO:0000269|PubMed:11311120, ECO:0000269|PubMed:12228231,
CC       ECO:0000269|PubMed:19221179, ECO:0000269|PubMed:20543840,
CC       ECO:0000269|PubMed:21245099, ECO:0000269|PubMed:25009184,
CC       ECO:0000269|PubMed:31063815}. Nucleus {ECO:0000269|PubMed:11311120,
CC       ECO:0000269|PubMed:12228231, ECO:0000269|PubMed:20543840,
CC       ECO:0000269|PubMed:25009184, ECO:0000269|PubMed:31063815}.
CC       Note=Shuttles between the cytoplasm and nucleus. Largely nuclear in
CC       unstimulated cells (PubMed:11311120, PubMed:12228231, PubMed:19221179,
CC       PubMed:20543840, PubMed:21245099, PubMed:25009184). In osteoblasts,
CC       colocalizes with ATF4 and RUNX2 in the nucleus (By similarity). Serum
CC       deprivation increases localization to the nucleus, leading to activate
CC       expression of SOX9 and subsequent chondrogenesis (By similarity).
CC       Insulin-induced phosphorylation at Ser-256 by PKB/AKT1 leads, via
CC       stimulation of Thr-24 phosphorylation, to binding of 14-3-3 proteins
CC       and nuclear export to the cytoplasm where it is degraded by the
CC       ubiquitin-proteasomal pathway (PubMed:11237865, PubMed:12228231).
CC       Phosphorylation at Ser-249 by CDK1 disrupts binding of 14-3-3 proteins
CC       and promotes nuclear accumulation (PubMed:18356527). Phosphorylation by
CC       NLK results in nuclear export (By similarity). Translocates to the
CC       nucleus upon oxidative stress-induced phosphorylation at Ser-212 by
CC       STK4/MST1 (PubMed:19221179, PubMed:21245099). SGK1-mediated
CC       phosphorylation also results in nuclear translocation (By similarity).
CC       Retained in the nucleus under stress stimuli including oxidative
CC       stress, nutrient deprivation or nitric oxide (By similarity). Retained
CC       in the nucleus on methylation (By similarity). PPIA/CYPA stimulates its
CC       nuclear accumulation (PubMed:31063815). Deacetylation by SIRT6,
CC       promotes its translocation into the cytoplasm (PubMed:25009184).
CC       {ECO:0000250|UniProtKB:Q9R1E0, ECO:0000269|PubMed:11237865,
CC       ECO:0000269|PubMed:11311120, ECO:0000269|PubMed:12228231,
CC       ECO:0000269|PubMed:18356527, ECO:0000269|PubMed:19221179,
CC       ECO:0000269|PubMed:20543840, ECO:0000269|PubMed:21245099,
CC       ECO:0000269|PubMed:25009184, ECO:0000269|PubMed:31063815}.
CC   -!- TISSUE SPECIFICITY: Expressed in umbilical endothelial cells (at
CC       protein level) (PubMed:19483080). Abundantly expressed in skeletal
CC       muscle and ovary, with lower expression in the heart, placenta, lung,
CC       liver, pancreas, spleen, testis and small intestine (PubMed:9479491).
CC       Weakly expressed in the brain, thymus, prostate and mucosal lining of
CC       the colon (PubMed:9479491). {ECO:0000269|PubMed:19483080,
CC       ECO:0000269|PubMed:9479491}.
CC   -!- INDUCTION: Expression is regulated by KRIT1. Levels of expression also
CC       regulated by FOXC1 which binds to a conserved element in the FOXO1
CC       promoter. {ECO:0000269|PubMed:20668652}.
CC   -!- PTM: Phosphorylation by NLK promotes nuclear export and inhibits the
CC       transcriptional activity. In response to growth factors,
CC       phosphorylation on Thr-24, Ser-256 and Ser-322 by PKB/AKT1 promotes
CC       nuclear export and inactivation of transactivational activity.
CC       Phosphorylation on Thr-24 is required for binding 14-3-3 proteins.
CC       Phosphorylation of Ser-256 decreases DNA-binding activity and promotes
CC       the phosphorylation of Thr-24 and Ser-319, permitting phosphorylation
CC       of Ser-322 and Ser-325, probably by CDK1, leading to nuclear exclusion
CC       and loss of function. Stress signals, such as response to oxygen or
CC       nitric oxide, attenuate the PKB/AKT1-mediated phosphorylation leading
CC       to nuclear retention. Phosphorylation of Ser-329 is independent of IGF1
CC       and leads to reduced function. Dephosphorylated on Thr-24 and Ser-256
CC       by PP2A in beta-cells under oxidative stress leading to nuclear
CC       retention (By similarity). Phosphorylation of Ser-249 by CDK1 disrupts
CC       binding of 14-3-3 proteins leading to nuclear accumulation and has no
CC       effect on DNA-binding nor transcriptional activity. Phosphorylation by
CC       STK4/MST1 on Ser-212, upon oxidative stress, inhibits binding to 14-3-3
CC       proteins and nuclear export. PPIA/CYPA promotes its dephosphorylation
CC       on Ser-256 (PubMed:31063815). {ECO:0000250|UniProtKB:Q9R1E0,
CC       ECO:0000269|PubMed:10358075, ECO:0000269|PubMed:10358076,
CC       ECO:0000269|PubMed:11237865, ECO:0000269|PubMed:11311120,
CC       ECO:0000269|PubMed:11980723, ECO:0000269|PubMed:18356527,
CC       ECO:0000269|PubMed:18786403, ECO:0000269|PubMed:19221179,
CC       ECO:0000269|PubMed:21245099, ECO:0000269|PubMed:31063815}.
CC   -!- PTM: Ubiquitinated by SKP2 (PubMed:15668399). Ubiquitination leads to
CC       proteasomal degradation (PubMed:19483080). Ubiquitinated by STUB1/CHIP;
CC       when Ser-256 is phosphorylated (PubMed:19483080).
CC       {ECO:0000269|PubMed:15668399, ECO:0000269|PubMed:19483080}.
CC   -!- PTM: Methylation inhibits AKT1-mediated phosphorylation at Ser-256 and
CC       is increased by oxidative stress. {ECO:0000250|UniProtKB:Q9R1E0}.
CC   -!- PTM: Acetylated (PubMed:15220471, PubMed:15890677, PubMed:18786403,
CC       PubMed:20543840). Acetylation at Lys-262, Lys-265 and Lys-274 are
CC       necessary for autophagic cell death induction (PubMed:20543840).
CC       Deacetylated by SIRT2 in response to oxidative stress or serum
CC       deprivation, thereby negatively regulating FOXO1-mediated autophagic
CC       cell death (PubMed:20543840). Once in the nucleus, acetylated by
CC       CREBBP/EP300 (PubMed:15220471, PubMed:15890677, PubMed:18786403).
CC       Acetylation diminishes the interaction with target DNA and attenuates
CC       the transcriptional activity. It increases the phosphorylation at Ser-
CC       256 (PubMed:15220471, PubMed:15890677, PubMed:18786403). Deacetylation
CC       by SIRT1 results in reactivation of the transcriptional activity
CC       (PubMed:15220471, PubMed:15890677, PubMed:18786403). Oxidative stress
CC       by hydrogen peroxide treatment appears to promote deacetylation and
CC       uncoupling of insulin-induced phosphorylation (PubMed:15220471,
CC       PubMed:15890677, PubMed:18786403). By contrast, resveratrol acts
CC       independently of acetylation (PubMed:15220471, PubMed:15890677,
CC       PubMed:18786403). Acetylated at Lys-423, promoting its localization to
CC       the nucleus and transcription factor activity (PubMed:25009184).
CC       Deacetylation at Lys-423 by SIRT6, promotes its translocation into the
CC       cytoplasm, preventing its transcription factor activity
CC       (PubMed:25009184). Deacetylation and subsequent inhibition by SIRT6 has
CC       different effects depending on cell types: it inhibits gluconeogenesis
CC       in hepatocytes, promotes glucose sensing in pancreatic beta-cells and
CC       regulates lipid catabolism in brown adipocytes (By similarity).
CC       {ECO:0000250|UniProtKB:Q9R1E0, ECO:0000269|PubMed:15220471,
CC       ECO:0000269|PubMed:15890677, ECO:0000269|PubMed:18786403,
CC       ECO:0000269|PubMed:20543840, ECO:0000269|PubMed:25009184}.
CC   -!- DISEASE: Rhabdomyosarcoma 2 (RMS2) [MIM:268220]: A form of
CC       rhabdomyosarcoma, a highly malignant tumor of striated muscle derived
CC       from primitive mesenchymal cells and exhibiting differentiation along
CC       rhabdomyoblastic lines. Rhabdomyosarcoma is one of the most frequently
CC       occurring soft tissue sarcomas and the most common in children. It
CC       occurs in four forms: alveolar, pleomorphic, embryonal and botryoidal
CC       rhabdomyosarcomas. Note=The gene represented in this entry may be
CC       involved in disease pathogenesis. Chromosomal aberrations involving
CC       FOXO1 are found in rhabdomyosarcoma. Translocation (2;13)(q35;q14) with
CC       PAX3 and translocation t(1;13)(p36;q14) with PAX7. The resulting
CC       protein is a transcriptional activator. {ECO:0000269|PubMed:8275086}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/83/FOXO1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U02310; AAA03629.1; -; mRNA.
DR   EMBL; AF032885; AAC39591.1; -; mRNA.
DR   EMBL; BT007455; AAP36123.1; -; mRNA.
DR   EMBL; AL355132; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL133318; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC021981; AAH21981.1; -; mRNA.
DR   EMBL; BC070065; AAH70065.3; -; mRNA.
DR   CCDS; CCDS9371.1; -.
DR   PIR; S40521; S40521.
DR   RefSeq; NP_002006.2; NM_002015.3.
DR   PDB; 3CO6; X-ray; 2.10 A; C=151-249.
DR   PDB; 3CO7; X-ray; 2.91 A; C/F=151-266.
DR   PDB; 3COA; X-ray; 2.20 A; C/F=151-266.
DR   PDB; 4LG0; X-ray; 2.19 A; A=143-270.
DR   PDB; 5DUI; X-ray; 2.31 A; A/B=151-259.
DR   PDB; 6LBI; X-ray; 3.07 A; C/D/G/H/K/L=151-265.
DR   PDB; 6QVW; NMR; -; A=159-272.
DR   PDB; 6QZR; X-ray; 2.30 A; J/M/N/O/P/R/T/U=19-29.
DR   PDB; 6QZS; X-ray; 1.90 A; C/P=251-262.
DR   PDB; 8A62; X-ray; 1.60 A; B=20-29.
DR   PDB; 8A65; X-ray; 1.60 A; B=21-28.
DR   PDBsum; 3CO6; -.
DR   PDBsum; 3CO7; -.
DR   PDBsum; 3COA; -.
DR   PDBsum; 4LG0; -.
DR   PDBsum; 5DUI; -.
DR   PDBsum; 6LBI; -.
DR   PDBsum; 6QVW; -.
DR   PDBsum; 6QZR; -.
DR   PDBsum; 6QZS; -.
DR   PDBsum; 8A62; -.
DR   PDBsum; 8A65; -.
DR   AlphaFoldDB; Q12778; -.
DR   SMR; Q12778; -.
DR   BioGRID; 108597; 334.
DR   CORUM; Q12778; -.
DR   DIP; DIP-35654N; -.
DR   FunCoup; Q12778; 2941.
DR   IntAct; Q12778; 42.
DR   MINT; Q12778; -.
DR   STRING; 9606.ENSP00000368880; -.
DR   BindingDB; Q12778; -.
DR   ChEMBL; CHEMBL5294; -.
DR   GlyConnect; 2844; 1 O-GlcNAc glycan (4 sites).
DR   GlyCosmos; Q12778; 7 sites, 1 glycan.
DR   GlyGen; Q12778; 7 sites, 1 O-linked glycan (7 sites).
DR   iPTMnet; Q12778; -.
DR   PhosphoSitePlus; Q12778; -.
DR   BioMuta; FOXO1; -.
DR   DMDM; 116241368; -.
DR   CPTAC; CPTAC-1323; -.
DR   CPTAC; non-CPTAC-5703; -.
DR   jPOST; Q12778; -.
DR   MassIVE; Q12778; -.
DR   PaxDb; 9606-ENSP00000368880; -.
DR   PeptideAtlas; Q12778; -.
DR   ProteomicsDB; 58922; -.
DR   Pumba; Q12778; -.
DR   Antibodypedia; 645; 2165 antibodies from 52 providers.
DR   CPTC; Q12778; 3 antibodies.
DR   DNASU; 2308; -.
DR   Ensembl; ENST00000379561.6; ENSP00000368880.4; ENSG00000150907.10.
DR   GeneID; 2308; -.
DR   KEGG; hsa:2308; -.
DR   MANE-Select; ENST00000379561.6; ENSP00000368880.4; NM_002015.4; NP_002006.2.
DR   UCSC; uc001uxl.5; human.
DR   AGR; HGNC:3819; -.
DR   CTD; 2308; -.
DR   DisGeNET; 2308; -.
DR   GeneCards; FOXO1; -.
DR   HGNC; HGNC:3819; FOXO1.
DR   HPA; ENSG00000150907; Tissue enhanced (skeletal).
DR   MalaCards; FOXO1; -.
DR   MIM; 136533; gene.
DR   MIM; 268220; phenotype.
DR   OpenTargets; ENSG00000150907; -.
DR   Orphanet; 99756; Alveolar rhabdomyosarcoma.
DR   VEuPathDB; HostDB:ENSG00000150907; -.
DR   eggNOG; KOG2294; Eukaryota.
DR   GeneTree; ENSGT00940000161558; -.
DR   HOGENOM; CLU_023456_1_1_1; -.
DR   InParanoid; Q12778; -.
DR   OMA; SHTMQMN; -.
DR   OrthoDB; 5954824at2759; -.
DR   PAN-GO; Q12778; 5 GO annotations based on evolutionary models.
DR   PhylomeDB; Q12778; -.
DR   PathwayCommons; Q12778; -.
DR   Reactome; R-HSA-198693; AKT phosphorylates targets in the nucleus.
DR   Reactome; R-HSA-210745; Regulation of gene expression in beta cells.
DR   Reactome; R-HSA-211163; AKT-mediated inactivation of FOXO1A.
DR   Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer.
DR   Reactome; R-HSA-5687128; MAPK6/MAPK4 signaling.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   Reactome; R-HSA-9614399; Regulation of localization of FOXO transcription factors.
DR   Reactome; R-HSA-9614657; FOXO-mediated transcription of cell death genes.
DR   Reactome; R-HSA-9615017; FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes.
DR   Reactome; R-HSA-9617629; Regulation of FOXO transcriptional activity by acetylation.
DR   Reactome; R-HSA-9617828; FOXO-mediated transcription of cell cycle genes.
DR   SignaLink; Q12778; -.
DR   SIGNOR; Q12778; -.
DR   BioGRID-ORCS; 2308; 19 hits in 1175 CRISPR screens.
DR   ChiTaRS; FOXO1; human.
DR   EvolutionaryTrace; Q12778; -.
DR   GeneWiki; FOXO1; -.
DR   GenomeRNAi; 2308; -.
DR   Pharos; Q12778; Tbio.
DR   PRO; PR:Q12778; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   RNAct; Q12778; protein.
DR   Bgee; ENSG00000150907; Expressed in decidua and 219 other cell types or tissues.
DR   GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; ISS:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0008013; F:beta-catenin binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0003682; F:chromatin binding; ISS:UniProtKB.
DR   GO; GO:0031490; F:chromatin DNA binding; IEA:Ensembl.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:UniProtKB.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProt.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IEA:Ensembl.
DR   GO; GO:0003676; F:nucleic acid binding; EXP:DisProt.
DR   GO; GO:1990841; F:promoter-specific chromatin binding; IEA:Ensembl.
DR   GO; GO:0051721; F:protein phosphatase 2A binding; ISS:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IMP:UniProtKB.
DR   GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0001568; P:blood vessel development; IEA:Ensembl.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0070417; P:cellular response to cold; ISS:UniProtKB.
DR   GO; GO:0071455; P:cellular response to hyperoxia; IDA:UniProtKB.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; ISS:UniProtKB.
DR   GO; GO:0071732; P:cellular response to nitric oxide; ISS:UniProtKB.
DR   GO; GO:0034599; P:cellular response to oxidative stress; ISS:UniProtKB.
DR   GO; GO:0009267; P:cellular response to starvation; IDA:UniProtKB.
DR   GO; GO:0006974; P:DNA damage response; ISS:UniProtKB.
DR   GO; GO:0097009; P:energy homeostasis; ISS:UniProtKB.
DR   GO; GO:0045444; P:fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:0010467; P:gene expression; IEA:Ensembl.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0001678; P:intracellular glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:1903243; P:negative regulation of cardiac muscle hypertrophy in response to stress; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; ISS:UniProtKB.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:0046676; P:negative regulation of insulin secretion; ISS:UniProtKB.
DR   GO; GO:0032873; P:negative regulation of stress-activated MAPK cascade; IDA:BHF-UCL.
DR   GO; GO:0097150; P:neuronal stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0010508; P:positive regulation of autophagy; IMP:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0045722; P:positive regulation of gluconeogenesis; IDA:UniProtKB.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0034393; P:positive regulation of smooth muscle cell apoptotic process; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0006473; P:protein acetylation; ISS:UniProtKB.
DR   GO; GO:2000177; P:regulation of neural precursor cell proliferation; IEA:Ensembl.
DR   GO; GO:2000377; P:regulation of reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0060260; P:regulation of transcription initiation by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0070542; P:response to fatty acid; ISS:UniProtKB.
DR   GO; GO:0001659; P:temperature homeostasis; ISS:UniProtKB.
DR   CDD; cd20060; FH_FOXO1; 1.
DR   DisProt; DP01132; -.
DR   FunFam; 1.10.10.10:FF:000032; Forkhead box protein O4; 1.
DR   Gene3D; 1.10.10.10; Winged helix-like DNA-binding domain superfamily/Winged helix DNA-binding domain; 1.
DR   IDEAL; IID00464; -.
DR   InterPro; IPR047408; FH_FOXO1.
DR   InterPro; IPR001766; Fork_head_dom.
DR   InterPro; IPR032067; FOXO-TAD.
DR   InterPro; IPR032068; FOXO_KIX-bd.
DR   InterPro; IPR030456; TF_fork_head_CS_2.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   PANTHER; PTHR45767; FORKHEAD BOX PROTEIN O; 1.
DR   PANTHER; PTHR45767:SF1; FORKHEAD BOX PROTEIN O1; 1.
DR   Pfam; PF00250; Forkhead; 1.
DR   Pfam; PF16676; FOXO-TAD; 1.
DR   Pfam; PF16675; FOXO_KIX_bdg; 1.
DR   PRINTS; PR00053; FORKHEAD.
DR   SMART; SM00339; FH; 1.
DR   SUPFAM; SSF46785; Winged helix' DNA-binding domain; 1.
DR   PROSITE; PS00658; FORK_HEAD_2; 1.
DR   PROSITE; PS50039; FORK_HEAD_3; 1.
DR   neXtProt; NX_Q12778; -.
DR   PharmGKB; PA28237; -.
DR   TreeFam; TF315583; -.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Apoptosis; Autophagy;
KW   Chromosomal rearrangement; Cytoplasm; Differentiation; DNA-binding;
KW   Methylation; Nucleus; Phosphoprotein; Proteomics identification;
KW   Proto-oncogene; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN           1..655
FT                   /note="Forkhead box protein O1"
FT                   /id="PRO_0000091872"
FT   DNA_BIND        159..235
FT                   /note="Fork-head"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00089"
FT   REGION          1..63
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          116..158
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          211..218
FT                   /note="DNA-binding"
FT                   /evidence="ECO:0000269|PubMed:18786403"
FT   REGION          234..344
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          234..237
FT                   /note="DNA-binding"
FT                   /evidence="ECO:0000269|PubMed:18786403"
FT   REGION          283..563
FT                   /note="Sufficient for interaction with NLK"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R1E0"
FT   REGION          363..459
FT                   /note="Required for interaction with RUNX2"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R1E0"
FT   REGION          507..537
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           251..253
FT                   /note="Nuclear localization signal"
FT   MOTIF           462..466
FT                   /note="Required for interaction with SIRT1"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R1E0"
FT   COMPBIAS        33..63
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        120..141
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        264..275
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        309..326
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        507..534
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            158
FT                   /note="DNA-binding"
FT                   /evidence="ECO:0000269|PubMed:18786403"
FT   SITE            165
FT                   /note="DNA-binding"
FT                   /evidence="ECO:0000269|PubMed:18786403"
FT   SITE            225
FT                   /note="DNA-binding"
FT                   /evidence="ECO:0000269|PubMed:18786403"
FT   MOD_RES         24
FT                   /note="Phosphothreonine; by PKB/AKT1 or PKB/AKT2 and SGK1"
FT                   /evidence="ECO:0000269|PubMed:10358075,
FT                   ECO:0000269|PubMed:11237865, ECO:0000269|PubMed:11980723"
FT   MOD_RES         212
FT                   /note="Phosphoserine; by STK4/MST1"
FT                   /evidence="ECO:0000269|PubMed:18786403,
FT                   ECO:0000269|PubMed:19221179, ECO:0000269|PubMed:21245099"
FT   MOD_RES         218
FT                   /note="Phosphoserine; by STK4/MST1"
FT                   /evidence="ECO:0000269|PubMed:18786403"
FT   MOD_RES         234
FT                   /note="Phosphoserine; by STK4/MST1"
FT                   /evidence="ECO:0000269|PubMed:18786403"
FT   MOD_RES         235
FT                   /note="Phosphoserine; by STK4/MST1"
FT                   /evidence="ECO:0000269|PubMed:18786403"
FT   MOD_RES         245
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R1E0"
FT   MOD_RES         248
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R1E0"
FT   MOD_RES         249
FT                   /note="Phosphoserine; by CDK1"
FT                   /evidence="ECO:0000269|PubMed:18356527"
FT   MOD_RES         251
FT                   /note="Omega-N-methylarginine; by PRMT1"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R1E0"
FT   MOD_RES         253
FT                   /note="Omega-N-methylarginine; by PRMT1"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R1E0"
FT   MOD_RES         256
FT                   /note="Phosphoserine; by PKB/AKT1 and SGK1"
FT                   /evidence="ECO:0000269|PubMed:10358075,
FT                   ECO:0000269|PubMed:10358076, ECO:0000269|PubMed:11237865,
FT                   ECO:0000269|PubMed:11980723, ECO:0000269|PubMed:31063815"
FT   MOD_RES         262
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:20543840"
FT   MOD_RES         265
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:20543840"
FT   MOD_RES         274
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:20543840"
FT   MOD_RES         287
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692"
FT   MOD_RES         298
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R1E0"
FT   MOD_RES         319
FT                   /note="Phosphoserine; by PKB/AKT1"
FT                   /evidence="ECO:0000269|PubMed:10358075,
FT                   ECO:0000269|PubMed:11237865, ECO:0000269|PubMed:11980723"
FT   MOD_RES         322
FT                   /note="Phosphoserine; by CK1 and SGK1"
FT                   /evidence="ECO:0000269|PubMed:11980723"
FT   MOD_RES         325
FT                   /note="Phosphoserine; by CK1"
FT                   /evidence="ECO:0000269|PubMed:11980723"
FT   MOD_RES         329
FT                   /note="Phosphoserine; by DYRK1A"
FT                   /evidence="ECO:0000269|PubMed:11311120,
FT                   ECO:0000269|PubMed:11980723"
FT   MOD_RES         333
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R1E0"
FT   MOD_RES         423
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:25009184"
FT   MUTAGEN         24
FT                   /note="T->A: Abolishes PKB/AKT1-mediated phosphorylation
FT                   but does not prevent phosphorylation of Ser-256 or Ser-319.
FT                   Also inhibits binding of 14-3-3 proteins. Nuclear in
FT                   unstimulated cells, and little export to cytoplasm on IGF1
FT                   stimulation. Targeted to the nucleus and enhances
FT                   transactivation; when associated with A-319. No effect on
FT                   interaction with STUB1. Inhibits the PKB/AKT1-mediated
FT                   activity towards other substrates but does not block the
FT                   IGF1-activated 'T-308' of phosphorylation of PKB/AKT1; when
FT                   associated with A-256 and A-319."
FT                   /evidence="ECO:0000269|PubMed:11237865,
FT                   ECO:0000269|PubMed:12228231, ECO:0000269|PubMed:19483080"
FT   MUTAGEN         212
FT                   /note="S->A: Abolishes STK4/MST1-mediated phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:19221179"
FT   MUTAGEN         245
FT                   /note="K->A: Disrupts DNA-binding; when associated with
FT                   A-248."
FT                   /evidence="ECO:0000269|PubMed:12228231"
FT   MUTAGEN         248
FT                   /note="K->A: Disrupts DNA-binding; when associated with
FT                   A-245."
FT                   /evidence="ECO:0000269|PubMed:12228231"
FT   MUTAGEN         249
FT                   /note="S->A: Impaired phosphorylation by CDK1."
FT                   /evidence="ECO:0000269|PubMed:18356527,
FT                   ECO:0000269|PubMed:18786403"
FT   MUTAGEN         249
FT                   /note="S->E: No effect on DNA-binding."
FT                   /evidence="ECO:0000269|PubMed:18356527,
FT                   ECO:0000269|PubMed:18786403"
FT   MUTAGEN         251..253
FT                   /note="RRR->SAS: No targeting to the nucleus and disruption
FT                   of DNA-binding."
FT                   /evidence="ECO:0000269|PubMed:12228231"
FT   MUTAGEN         256
FT                   /note="S->A: Completely abolishes PKB/AKT1-mediated
FT                   phosphorylation at all three sites, and inhibits binding of
FT                   14-3-3 proteins. Inhibits the PKB/AKT1-mediated activity
FT                   towards other substrates but does not block the
FT                   IGF1-activated 'T-308' of phosphorylation of PKB/AKT1; when
FT                   associated with or without A-24 and A-319. Nuclear in
FT                   unstimulated cells, and little export to cytoplasm on IGF1
FT                   stimulation. Abolishes the ability of IGF1 to suppress
FT                   transactivation. Prevents T-24 and S-319 phosphorylation.
FT                   Abolishes interaction with and ubiquitination by STUB1.
FT                   Enhances transactivation; when associated with A-24 and
FT                   A-319."
FT                   /evidence="ECO:0000269|PubMed:11237865,
FT                   ECO:0000269|PubMed:12228231, ECO:0000269|PubMed:15668399,
FT                   ECO:0000269|PubMed:19483080"
FT   MUTAGEN         256
FT                   /note="S->D: Reduces DNA binding, promotes nuclear
FT                   exclusion and partially promotes T-24 and S-319
FT                   phosphorylation. Reduces DNA binding, does not promote
FT                   nuclear exclusion but reduces transactivation; when
FT                   associated with A-24 and A-319."
FT                   /evidence="ECO:0000269|PubMed:11237865,
FT                   ECO:0000269|PubMed:12228231, ECO:0000269|PubMed:15668399"
FT   MUTAGEN         262
FT                   /note="K->R: Inhibits interaction with ATG7 and
FT                   FOXO1-acetylation-induced autophagic cell death; when
FT                   associated with R-265 and R-274."
FT                   /evidence="ECO:0000269|PubMed:12228231"
FT   MUTAGEN         265
FT                   /note="K->R: Inhibits interaction with ATG7 and
FT                   FOXO1-acetylation-induced autophagic cell death; when
FT                   associated with R-262 and R-274."
FT                   /evidence="ECO:0000269|PubMed:12228231"
FT   MUTAGEN         274
FT                   /note="K->R: Inhibits interaction with ATG7 and
FT                   FOXO1-acetylation-induced autophagic cell death; when
FT                   associated with R-262 and R-265."
FT                   /evidence="ECO:0000269|PubMed:12228231"
FT   MUTAGEN         319
FT                   /note="S->A: Abolishes PKB/AKT1-mediated phosphorylation
FT                   but does not prevent phosphorylation of Ser-24 or Ser-256.
FT                   Inhibits the PKB/AKT1-mediated activity towards other
FT                   substrates but does not block the IGF1-activated 'T-308' of
FT                   phosphorylation of PKB/AKT1; when associated with A-24 and
FT                   A-256. Targeted to the nucleus and enhances
FT                   transactivation; when associated with A-24. No effect on
FT                   interaction with STUB1."
FT                   /evidence="ECO:0000269|PubMed:11237865,
FT                   ECO:0000269|PubMed:12228231, ECO:0000269|PubMed:19483080"
FT   MUTAGEN         329
FT                   /note="S->A: Targeted to the nucleus and enhances
FT                   transactivation."
FT                   /evidence="ECO:0000269|PubMed:11311120"
FT   MUTAGEN         423
FT                   /note="K->R: Abolished deacetylation by SIRT6."
FT                   /evidence="ECO:0000269|PubMed:25009184"
FT   MUTAGEN         446
FT                   /note="K->R: Does not affect deacetylation by SIRT6."
FT                   /evidence="ECO:0000269|PubMed:25009184"
FT   MUTAGEN         463
FT                   /note="K->R: Does not affect deacetylation by SIRT6."
FT                   /evidence="ECO:0000269|PubMed:25009184"
FT   MUTAGEN         515
FT                   /note="K->R: Does not affect deacetylation by SIRT6."
FT                   /evidence="ECO:0000269|PubMed:25009184"
FT   CONFLICT        131
FT                   /note="L -> V (in Ref. 1; AAA03629)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        343
FT                   /note="V -> M (in Ref. 5; AAH70065)"
FT                   /evidence="ECO:0000305"
FT   STRAND          156..158
FT                   /evidence="ECO:0007829|PDB:3CO6"
FT   HELIX           165..175
FT                   /evidence="ECO:0007829|PDB:3CO6"
FT   STRAND          176..181
FT                   /evidence="ECO:0007829|PDB:5DUI"
FT   HELIX           183..193
FT                   /evidence="ECO:0007829|PDB:3CO6"
FT   HELIX           195..197
FT                   /evidence="ECO:0007829|PDB:3CO6"
FT   HELIX           203..219
FT                   /evidence="ECO:0007829|PDB:3CO6"
FT   STRAND          223..226
FT                   /evidence="ECO:0007829|PDB:3CO6"
FT   TURN            230..232
FT                   /evidence="ECO:0007829|PDB:3CO6"
FT   STRAND          236..239
FT                   /evidence="ECO:0007829|PDB:3CO6"
SQ   SEQUENCE   655 AA;  69662 MW;  6DEF6C994BDFDBAB CRC64;
     MAEAPQVVEI DPDFEPLPRP RSCTWPLPRP EFSQSNSATS SPAPSGSAAA NPDAAAGLPS
     ASAAAVSADF MSNLSLLEES EDFPQAPGSV AAAVAAAAAA AATGGLCGDF QGPEAGCLHP
     APPQPPPPGP LSQHPPVPPA AAGPLAGQPR KSSSSRRNAW GNLSYADLIT KAIESSAEKR
     LTLSQIYEWM VKSVPYFKDK GDSNSSAGWK NSIRHNLSLH SKFIRVQNEG TGKSSWWMLN
     PEGGKSGKSP RRRAASMDNN SKFAKSRSRA AKKKASLQSG QEGAGDSPGS QFSKWPASPG
     SHSNDDFDNW STFRPRTSSN ASTISGRLSP IMTEQDDLGE GDVHSMVYPP SAAKMASTLP
     SLSEISNPEN MENLLDNLNL LSSPTSLTVS TQSSPGTMMQ QTPCYSFAPP NTSLNSPSPN
     YQKYTYGQSS MSPLPQMPIQ TLQDNKSSYG GMSQYNCAPG LLKELLTSDS PPHNDIMTPV
     DPGVAQPNSR VLGQNVMMGP NSVMSTYGSQ ASHNKMMNPS SHTHPGHAQQ TSAVNGRPLP
     HTVSTMPHTS GMNRLTQVKT PVQVPLPHPM QMSALGGYSS VSSCNGYGRM GLLHQEKLPS
     DLDGMFIERL DCDMESIIRN DLMDGDTLDF NFDNVLPNQS FPHSVKTTTH SWVSG
//
